aTYR PHARMA INC (ATYR) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-13

Key Insights

Director Paul Schimmel received a grant of 50,000 stock options at $0.95 exercise price on 05/11/2026, vesting in full by May 2027, representing standard non-employee director compensation with no immediate stock acquisition.
The option grant at $0.95 per share is relatively modest in value and represents routine equity compensation rather than significant insider confidence in future stock price appreciation.
No non-derivative securities were acquired or disposed of in this transaction, indicating this is purely a compensation grant rather than open market buying activity that might signal insider bullishness.

Want the newest filings?

This analysis covers the filing from 2026-05-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-13

Director Timothy Coughlin received a grant of 50,000 stock options with a strike price of $0.95, exercisable for 10 years, indicating the company's current stock valuation is at or near this level.
The options vest on the earlier of May 11, 2027 or the 2027 Annual Shareholder Meeting, which is a standard non-employee director compensation arrangement with typical one-year vesting.
This is a routine equity compensation grant to a board member under the company's non-employee director compensation policy, not an insider purchase or sale that would signal confidence or concern about stock valuation.

Filed: 2026-05-13

Director Sara Zaknoen received a grant of 50,000 stock options with an exercise price of $0.95, vesting in full by May 11, 2027 or at the 2027 Annual Meeting, indicating the company is using equity compensation to retain board members.
The low exercise price of $0.95 per share suggests the stock was trading near or below this level at the time of grant (May 11, 2026), which may indicate weak stock performance or a down round valuation for the company.
This is a routine non-employee director compensation action under the company's standard equity plan, representing a typical board retention practice rather than a signal of insider confidence or significant business developments.

Filed: 2026-05-13

Director Lucas Svetlana received a grant of 50,000 stock options at an exercise price of $0.95, vesting on the earlier of May 11, 2027 or the 2027 Annual Meeting, reflecting standard non-employee director compensation.
The option grant represents routine equity compensation under aTYR's director compensation policy rather than evidence of insider conviction about stock value, as this is a scheduled award tied to board service.
No actual common stock purchases were made in this transaction, indicating no meaningful insider buying at current market prices despite the director's participation in the company's governance.

Filed: 2026-05-13

Director Jane A Gross received a grant of 50,000 stock options with a strike price of $0.95, vesting on the earlier of May 11, 2027 or the 2027 Annual Shareholder Meeting, representing standard non-employee director compensation.
The option strike price of $0.95 is notably low, suggesting the stock was trading near this level on the grant date (05/11/2026), which may indicate depressed valuation or financial challenges for the company.
This is a routine equity grant to a board member under the company's standard non-employee director compensation policy, with no significant insider buying or selling activity that would indicate insider confidence or concern.

Filed: 2026-05-13

Director Eric Benevich received a grant of 50,000 stock options with an exercise price of $0.95, vesting in full by May 11, 2027 or at the 2027 Annual Meeting, indicating standard non-employee director compensation.
The option grant represents routine equity compensation under aTYR's director compensation policy rather than a discretionary insider purchase, suggesting no material conviction signal about company valuation.
No actual securities were acquired or disposed of in this transaction—only derivative options were granted—limiting this filing's significance as an insider trading signal.

Filed: 2026-01-09

The reporting person, Nancy Denyes, acquired 31,555 shares of aTYR PHARMA INC (ATYR) common stock through the company's 2015 Employee Purchase Plan in multiple transactions.
Denyes was granted a stock option to purchase 412,500 shares of ATYR common stock at an exercise price of $0.7127 per share, which will vest in 36 equal monthly installments starting February 9, 2026.
The stock option is subject to accelerated vesting upon termination without cause upon a change of control of the issuer, providing an incentive for Denyes to remain with the company during a potential acquisition.

Other reports for aTYR PHARMA INC

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.